Roblitinib 是一种口服有效的，高选择性的FGFR4抑制剂 (IC50:1.9 nM)，具有抗癌作用。

FGF401 is an inhibitor of human fibroblast growth factor receptor 4 (FGFR4), with potential antineoplastic activity. Upon administration, FGF401 binds to and inhibits the activity of FGFR4, which leads to an inhibition of tumor cell proliferation in FGFR4-overexpressing cells. FGFR4 is a receptor tyrosine kinase upregulated in certain tumor cells and involved in tumor cell proliferation, differentiation, angiogenesis, and survival.

FGF-401 is a FGFR4 inhibitor developed for the treatment of solid tumor. FGF-401 is a FGFR4 inhibitor in phase I/II Clinicalal studies for the treatment of positive FGFR4 and KLB expresion solid tumors and hepatocellular carcinoma

1708971-55-4

C25H30N8O4

506.567

FGF-401

DMSO:10mM
Powder: -20°C for 3 years
In solvent: -80°C for 2 years